Navigation Links
Halogen Advances its Lead in Providing Employee Performance and Talent Management Solutions for the Healthcare Market
Date:1/31/2008

use of the information we collect."

The American Hospital Association (AHA) has identified and exclusively endorsed Halogen eAppraisal Healthcare as its EPM solution of choice for member hospitals and healthcare organizations across the United States.

"Our membership has identified employee performance management as a top priority as they address the increasingly difficult challenge of recruiting and retaining a highly-skilled workforce," said Amy Goble, VP of Account Management for AHA Solutions, Inc. "Halogen, with its healthcare specific version of eAppraisal, is a leader within the healthcare community, enabling facilities to address their performance management needs. Halogen is providing more and more hospitals with a complete, extremely simple system that provides comprehensive year-round employee reviews, clinical and orientation checklists and instant JCAHO ready reports."

About Halogen

A recognized and award-winning industry leader with over 1000 customers worldwide, Halogen Software is known for its powerful, simple-to-use and affordable employee performance and talent management applications. The company offers a complete suite of web-based products that automate, simplify and integrate employee performance management, 360/multi-rater feedback, compensation management, succession planning and learning management. Halogen's offering makes HR best-practices accessible to companies of all sizes and its healthcare, financial services and professional services specific suites meet the unique needs of these industries. Halogen is consistently recognized by the industry and its customers for its exceptional implementation and support services, and has won multiple awards for its corporate leadership and product innovation, including HR Technology Product of the Year. For more information, visit http://www.halogensoftware.com.


'/>"/>
SOURCE HALOGEN SOFTWARE
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Halogen Software Wins Top Human Resource Product Award
2. Move over, silicon: Advances pave way for powerful carbon-based electronics
3. Anavex advances drug candidate for treatment of Alzheimers disease
4. Response Genetics CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference
5. EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
6. Verenium Advances Its Development Work With Cargill on a New Food-Related Product
7. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
8. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
9. Kiwa Holds 2007 Annual Management Meetings and Employee Recognition Ceremonies in Beijing
10. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
11. Model is first to compare performance of biosensors
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4
Other Biology Technology:Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 2Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 3Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 4Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 5China Sky One Medical, Inc. Raises Guidance for 2008 Revenue and Net Income 2China Sky One Medical, Inc. Raises Guidance for 2008 Revenue and Net Income 3Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval) 2Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval) 3Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval) 4Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval) 5
Breaking Biology News(10 mins): Killer catfish? Venomous species surprisingly common, study finds 2Climate projections underestimate CO2 impact 2University of Texas Southwestern Medical Center researcher wins Avanti Award in lipids 2New National Poll Finds Americans Strongly Opposed to Cutting Medicare Payments for Nursing Home Care as a Means of Financing Health Care Reform 55742 1New National Poll Finds Americans Strongly Opposed to Cutting Medicare Payments for Nursing Home Care as a Means of Financing Health Care Reform 55742 2New National Poll Finds Americans Strongly Opposed to Cutting Medicare Payments for Nursing Home Care as a Means of Financing Health Care Reform 55742 3New National Poll Finds Americans Strongly Opposed to Cutting Medicare Payments for Nursing Home Care as a Means of Financing Health Care Reform 55742 4Noteworthy Medical Systems Demonstrates National Health Information Network 28NHIN 29 Interoperability 55739 1Noteworthy Medical Systems Demonstrates National Health Information Network 28NHIN 29 Interoperability 55739 2Noteworthy Medical Systems Demonstrates National Health Information Network 28NHIN 29 Interoperability 55739 3Do Good When You Shop and Help Educate a Generation of Healthy Kids 55736 1Do Good When You Shop and Help Educate a Generation of Healthy Kids 55736 2